Marta Jimenez

4.3k total citations · 1 hit paper
51 papers, 1.4k citations indexed

About

Marta Jimenez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Marta Jimenez has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Marta Jimenez's work include Cancer Genomics and Diagnostics (14 papers), Advanced Breast Cancer Therapies (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Marta Jimenez is often cited by papers focused on Cancer Genomics and Diagnostics (14 papers), Advanced Breast Cancer Therapies (10 papers) and Lung Cancer Treatments and Mutations (10 papers). Marta Jimenez collaborates with scholars based in France, Italy and United States. Marta Jimenez's co-authors include Thomas Bachelot, Véronique Dièras, Mario Campone, Anthony Gonçalvès, Florence Dalenc, Jean-­Marc Ferrero, Maya Gutierrez, Jean‐Yves Pierga, C. Labbé-Devilliers and Marianne Leheurteur and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Marta Jimenez

48 papers receiving 1.4k citations

Hit Papers

Lapatinib plus capecitabine in patients with previously u... 2012 2026 2016 2021 2012 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
    2012 522 citations Thomas Bachelot, Gilles Romieu et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marta Jimenez France 13 944 888 415 360 165 51 1.4k
Erin Macrae United States 13 445 0.5× 708 0.8× 360 0.9× 250 0.7× 82 0.5× 20 1.0k
Alex Pearson United Kingdom 9 823 0.9× 918 1.0× 537 1.3× 470 1.3× 219 1.3× 16 1.5k
Manuel Ruíz‐Borrego Spain 19 961 1.0× 1.3k 1.5× 771 1.9× 447 1.2× 142 0.9× 97 1.9k
S-A. Im South Korea 18 454 0.5× 799 0.9× 242 0.6× 324 0.9× 86 0.5× 85 1.1k
Gaia Griguolo Italy 24 431 0.5× 1.1k 1.2× 553 1.3× 269 0.7× 106 0.6× 87 1.4k
H. Léna France 19 978 1.0× 956 1.1× 178 0.4× 244 0.7× 136 0.8× 65 1.4k
Lesli A. Kiedrowski United States 15 630 0.7× 587 0.7× 716 1.7× 527 1.5× 115 0.7× 48 1.4k
Suparna Wedam United States 13 468 0.5× 907 1.0× 478 1.2× 364 1.0× 122 0.7× 30 1.4k
Lorenza Landi Italy 22 1.0k 1.1× 1.1k 1.3× 423 1.0× 611 1.7× 90 0.5× 85 1.8k

Countries citing papers authored by Marta Jimenez

Since Specialization
Citations

This map shows the geographic impact of Marta Jimenez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Jimenez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Jimenez more than expected).

Fields of papers citing papers by Marta Jimenez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Jimenez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Jimenez. The network helps show where Marta Jimenez may publish in the future.

Co-authorship network of co-authors of Marta Jimenez

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Jimenez. A scholar is included among the top collaborators of Marta Jimenez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Jimenez. Marta Jimenez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frenel, Jean‐Sébastien, Claire Cropet, Édith Borcoman, et al.. (2025). Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study. Journal for ImmunoTherapy of Cancer. 13(1). e010708–e010708. 1 indexed citations
2.
Lusque, Amélie, Véronique Dièras, Élise Deluche, et al.. (2024). 343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial. Annals of Oncology. 35. S359–S359. 2 indexed citations
3.
Vanacker, Hélène, Isabelle Treilleux, Camille Schiffler, et al.. (2024). p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British Journal of Cancer. 130(4). 613–619.
4.
Cesne, Axel Le, Christine Chevreau, Christophe Perrin, et al.. (2023). Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open. 8(3). 101569–101569. 9 indexed citations
5.
Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.
6.
7.
8.
9.
10.
11.
Irtan, Sabine, Jean Donadieu, Hélène Pacquement, et al.. (2022). Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma. Pediatric Blood & Cancer. 69(9). e29725–e29725. 1 indexed citations
12.
Lusque, Amélie, Véronique Dièras, Élise Deluche, et al.. (2022). LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial. Annals of Oncology. 33. S1440–S1440. 12 indexed citations
13.
Remón, Jordi, Benjamin Besse, Alexandra Léary, et al.. (2020). Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial. JTO Clinical and Research Reports. 1(3). 100068–100068. 19 indexed citations
14.
15.
Marec‐Bérard, Perrine, Valérie Laurence, Bob‐Valéry Occéan, et al.. (2019). Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years. Journal of Adolescent and Young Adult Oncology. 9(2). 172–182. 12 indexed citations
16.
Blay, Jean‐Yves, Julien Mazières, David Pérol, et al.. (2016). Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial. Annals of Oncology. 27. vi16–vi16. 3 indexed citations
17.
Dièras, Véronique, Thomas Bachelot, Mario Campone, et al.. (2016). A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study. Oncology and Therapy. 4(2). 211–223. 6 indexed citations
18.
Ravaud, Alain, Stéphane Oudard, Marc de Fromont, et al.. (2015). First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Annals of Oncology. 26(6). 1123–1128. 121 indexed citations
19.
André, Fabrice, Thomas Bachelot, Frédéric Commo, et al.. (2014). Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). The Lancet Oncology. 15(3). 267–274. 251 indexed citations
20.
Bachelot, Thomas, Gilles Romieu, Mario Campone, et al.. (2012). Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. The Lancet Oncology. 14(1). 64–71. 522 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erin Macrae Breakdown of academic impact, for papers by Alex Pearson Breakdown of academic impact, for papers by Manuel Ruíz‐Borrego Breakdown of academic impact, for papers by S-A. Im Breakdown of academic impact, for papers by Gaia Griguolo Breakdown of academic impact, for papers by H. Léna Breakdown of academic impact, for papers by Lesli A. Kiedrowski Breakdown of academic impact, for papers by Suparna Wedam Breakdown of academic impact, for papers by Lorenza Landi
Rankless by CCL
2026